Calendar

pharmadog

Week of Mar 30, 2026

Mar 31, 2026approval152d agoVALPROIC ACID — FDA approvalCereno Scientific AB

Sponsor: CHARTWELL RX. Form: SYRUP. Route: ORAL

full page →fda approvals ↗

Mar 31, 2026approval152d agoMESALAMINE — FDA approvalTakeda Pharmaceuticals USA Inc

Sponsor: KLM LABS PVT. Form: ENEMA. Route: RECTAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoLAMOTRIGINE — FDA approvalTorrent Pharma Inc

Sponsor: TARO PHARM INDS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoLAMOTRIGINE — FDA approvalTorrent Pharma Inc

Sponsor: TARO PHARM INDS. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoBOSENTAN — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

Sponsor: SUN PHARM. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoBOSENTAN — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

Sponsor: SUN PHARM. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoBOSENTAN — FDA approvalJanssen-Cilag Holdings Inc (Inactive)

Sponsor: SUN PHARM. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoVAFSEO (VADADUSTAT) — FDA approvalvadadustat

Sponsor: AKEBIA. Form: TABLET. Route: ORAL

full page →vadadustat →fda approvals ↗

Apr 1, 2026approval151d agoKESIMPTA (OFATUMUMAB) — FDA approvalKESIMPTA

Sponsor: NOVARTIS. Form: SOLUTION. Route: SUBCUTANEOUS

full page →KESIMPTA →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoLIDOCAINE HYDROCHLORIDE AND EPINEPHRINE (EPINEPHRINE) — FDA approvaladrenaline

Sponsor: HOSPIRA. Form: INJECTABLE. Route: INJECTION

full page →adrenaline →fda approvals ↗

Apr 1, 2026approval151d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

full page →BREXPIPRAZOLE →fda approvals ↗

Apr 1, 2026approval151d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

full page →BREXPIPRAZOLE →fda approvals ↗

Apr 1, 2026approval151d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

full page →BREXPIPRAZOLE →fda approvals ↗

Apr 1, 2026approval151d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

full page →BREXPIPRAZOLE →fda approvals ↗

Apr 1, 2026approval151d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

full page →BREXPIPRAZOLE →fda approvals ↗

Apr 1, 2026approval151d agoFOUNDAYO (ORFORGLIPRON CALCIUM) — FDA approvalorforglipron calcium

Sponsor: ELI LILLY AND CO. Form: TABLET. Route: ORAL

full page →orforglipron calcium →fda approvals ↗

Apr 1, 2026approval151d agoPROCHLORPERAZINE EDISYLATE — FDA approvalPROCHLORPERAZINE EDISYLATE

Sponsor: SOMERSET THERAPS LLC. Form: INJECTABLE. Route: INJECTION

full page →PROCHLORPERAZINE EDISYLATE →fda approvals ↗

Apr 1, 2026recall151d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 20 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9259-08. — Reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoMACLEODS PHARMA USA, INC recall (Cls II)Macleods Pharma USA Inc

Levothyroxine Sodium Tablets USP 150 mcg, 1000 Tablets bottle, Rx Only, Manufactured for: Macleods Pharma USA, Inc., Princeton, NJ, Manufactured by: Macleods Pharmaceuticals Ltd., Sarigam, Valsad, Guajarat, INDIA NDC 33342-401-44 — Reason: Subpotent Drug — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 10 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9257-08. — Reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoTeva Pharmaceuticals USA, Inc recall (Cls II)Terns Pharmaceuticals, Inc.

Octreotide Acetate for Injectable Suspension, for gluteal intramuscular use, 30 mg, Single-dose 8 mL vial, Rx only, Manufactured in Greece BY: Pharmathen International S.A, Rodopi, 693 00 Greece, Manufactured For: TEVA Pharmaceuticals, Parsippany, NJ 07054, NDC 0480-9262-08. — Reason: Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer. — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoAmerisource Health Services LLC recall (Cls II)Casper Pharma LLC

Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60687-775-65) (b) 12.5 mg Individual Dose ( NDC 60687-775-11), Rx Only, Distributed by: American Health Packaging, Columbus, Ohio, 43217. — Reason: Failed tablet specifications. — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoRadnostix recall (Cls III)RADNOSTIX INC

Gelatin Capsule Pack for use with the Sodium Iodide I-131 Kit (containing 5 empty capsules and 5 Dibasic Sodium Phosphate Capsules 300 mg, International Isotopes Inc., Idaho Falls, ID 83401. NDC: 69208-003-15; 69208-003-25; 69208-003-35 — Reason: Failed Tablet/Capsule Specifications — Status: Ongoing

full page →fda recalls ↗

Apr 1, 2026recall151d agoChiesi USA, Inc. recall (Cls II)Chiesi USA Inc

CUROSURF (poractant alfa), 240 mg, Intratracheal Suspension, 3L Single-dose-Vial, Rx only, Chiesi USA, Inc, Cary, NC 27518, NDC 10122-510-03. — Reason: Lack of Assurance of Sterility — Status: Ongoing

full page →fda recalls ↗

Apr 2, 2026approval150d agoNINTEDANIB ESYLATE — FDA approvalBoehringer Ingelheim Corp

Sponsor: DR REDDYS. Form: CAPSULE. Route: ORAL

full page →fda approvals ↗

Apr 2, 2026approval150d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

Sponsor: HERITAGE PHARMA. Form: TABLET. Route: ORAL

full page →ACETAZOLAMIDE →fda approvals ↗

Apr 2, 2026approval150d agoNINTEDANIB ESYLATE — FDA approvalOfev

Sponsor: SANDOZ. Form: CAPSULE. Route: ORAL

full page →Ofev →fda approvals ↗

Apr 2, 2026approval150d agoEYLEA HD (AFLIBERCEPT) — FDA approvalEYLEA HD

Sponsor: REGENERON PHARMACEUTICALS. Form: INJECTABLE. Route: INJECTION

full page →EYLEA HD →fda approvals ↗

Apr 2, 2026approval150d agoGABAPENTIN — FDA approvalAlmatica Pharma LLC

Sponsor: ALKEM LABS LTD. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 2, 2026approval150d agoPALIPERIDONE — FDA approvalEskayef Pharmaceuticals Ltd

Sponsor: ACTAVIS LABS FL INC. Form: TABLET, EXTENDED RELEASE. Route: ORAL

full page →fda approvals ↗

Apr 2, 2026approval150d agoNINTEDANIB ESYLATE — FDA approvalOfev

Sponsor: CIPLA. Form: CAPSULE. Route: ORAL

full page →Ofev →fda approvals ↗

Apr 2, 2026approval150d agoGABAPENTIN — FDA approvalGABAPENTIN

Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

full page →GABAPENTIN →fda approvals ↗

Apr 2, 2026approval150d agoNINTEDANIB ESYLATE — FDA approvalOfev

Sponsor: DEXCEL. Form: CAPSULE. Route: ORAL

full page →Ofev →fda approvals ↗

Apr 2, 2026approval150d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

Sponsor: NOVITIUM PHARMA. Form: TABLET. Route: ORAL

full page →ACETAZOLAMIDE →fda approvals ↗

Apr 2, 2026approval150d agoACETAZOLAMIDE — FDA approvalACETAZOLAMIDE

Sponsor: MANKIND PHARMA. Form: TABLET. Route: ORAL

full page →ACETAZOLAMIDE →fda approvals ↗

Apr 2, 2026approval150d agoNINTEDANIB ESYLATE — FDA approvalOfev

Sponsor: APOTEX. Form: CAPSULE. Route: ORAL

full page →Ofev →fda approvals ↗

04/03/2026recall149d agoWawa recall: Food & Beverages, Allergens

Iced Tea Lemon, Iced Tea Diet Lemon, Diet Lemonade and Fruit Punch

full page →fda recalls ↗

Apr 3, 2026approval149d agoGLYCOPYRRONIUM TOSYLATE — FDA approvalJourney Medical Corp

Sponsor: PADAGIS US. Form: CLOTH. Route: TOPICAL

full page →fda approvals ↗

Apr 3, 2026approval149d agoPHENYLEPHRINE HYDROCHLORIDE — FDA approvalPHENYLEPHRINE HYDROCHLORIDE

Sponsor: BAXTER HLTHCARE CORP. Form: SOLUTION. Route: INTRAVENOUS

full page →PHENYLEPHRINE HYDROCHLORIDE →fda approvals ↗

Apr 3, 2026approval149d agoTYVASO (TREPROSTINIL) — FDA approvalUNITED THERAPEUTICS Corp

Sponsor: UNITED THERAP. Form: SOLUTION. Route: INHALATION

full page →fda approvals ↗

Apr 3, 2026approval149d agoONDANSETRON HYDROCHLORIDE — FDA approvalRedHill Biopharma Ltd.

Sponsor: PHARM ASSOC. Form: SOLUTION. Route: ORAL

full page →fda approvals ↗

Week of Apr 6, 2026

Apr 6, 2026approval146d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

full page →fda approvals ↗

Apr 6, 2026approval

← prev

page 398 of 403

Week of Mar 30, 2026

Week of Apr 6, 2026